TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21267948

Group type: EXPERIMENTAL
Intervention: VIA intensive behavioral therapeutic program (n = 18)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Waitlist group (n = 18)
Number of subjects: 36
Study: 18389193

Group type: EXPERIMENTAL
Intervention: Topical 0.4% glycerol trinitrate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topical 2% calcium blocker
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Botulinum toxin injection into the internal sphincter
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lateral internal sphincterotomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fissurectomy combined with excision of skin tags and anal papilla
Number of subjects: 0
Study: 17319449

Group type: EXPERIMENTAL
Intervention: AVINZA (A-MQD), morphine sulfate extended-release capsules given once a day
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: AVINZA (A-MQD)
Number of subjects: 392

Group type: COMPARATOR
Intervention: OxyContin (O-ER), oxycodone modified-release tablets given twice a day
Number of subjects: 392
Study: 14748822

Group type: EXPERIMENTAL
Intervention: Posaconazole suspension (200 mg/5 ml) with a high-fat meal
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Posaconazole suspension (200 mg/5 ml) in fasting state
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Posaconazole suspension (200 mg/5 ml) with a nonfat meal
Number of subjects: 20

Group type: COMPARATOR
Intervention: Posaconazole tablets (2 x 100 mg) with a high-fat meal
Number of subjects: 20
Study: 11321849

Group type: EXPERIMENTAL
Intervention: 400 micrograms/day BDP‐AH (n = 98)
Number of subjects: 193

Group type: COMPARATOR
Intervention: 800 micrograms/day BUD‐DPI (n = 95)
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: 400 micrograms/day BDP‐AH
Number of subjects: 193

Group type: COMPARATOR
Intervention: 800 micrograms/day BUD‐DPI
Number of subjects: 193
Study: 9140689

Group type: EXPERIMENTAL
Intervention: EGb 761 (Tanakan, 320 mg/day, n = 8)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (n = 7)
Number of subjects: 15
Study: 7948798

Group type: EXPERIMENTAL
Intervention: 0.03% bupivacaine with fentanyl (4 micrograms/mL)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 0.06% bupivacaine with fentanyl (4 micrograms/mL)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 0.125% bupivacaine with fentanyl (4 micrograms/mL)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Plain fentanyl (control group)
Number of subjects: 40
Study: 2841591

Group type: EXPERIMENTAL
Intervention: Glucocorticoids (dexamethasone, prednisolone, depot‐ACTH)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Oral phosphate
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Sodium fluoride
Number of subjects: 11
Study: 29040219

Group type: EXPERIMENTAL
Intervention: High-impact training with calcium and vitamin D supplementation
Number of subjects: 36

Group type: COMPARATOR
Intervention: Walking at an intense pace (Control)
Number of subjects: 36
Study: 27343021

Group type: EXPERIMENTAL
Intervention: Health intervention package (classroom-based health education, hand-held personalized health record, health check)
Number of subjects: 435

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 435
Study: 24297633

Group type: EXPERIMENTAL
Intervention: Digital drainage system (Group A)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Traditional suction drainage system (Group B)
Number of subjects: 60
Study: 22079034

Group type: EXPERIMENTAL
Intervention: Sleep-deprived group
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 31
Study: 20845210

Group type: EXPERIMENTAL
Intervention: Kaempferia parviflora
Number of subjects: 35

Group type: COMPARATOR
Intervention: Starch placebo
Number of subjects: 35
Study: 19117179

Group type: EXPERIMENTAL
Intervention: Modified Tardieu Scale (MTS)
Number of subjects: 30
Study: 16651463

Group type: EXPERIMENTAL
Intervention: Nicotine (4‐mg tablet)
Number of subjects: 16
Study: 14670431

Group type: EXPERIMENTAL
Intervention: Contact ultrasound (US) biometry
Number of subjects: 36

Group type: COMPARATOR
Intervention: Immersion ultrasound (US) biometry
Number of subjects: 36
Study: 11191007

Group type: EXPERIMENTAL
Intervention: Ranitidine 50 mg tid intravenously alone (Group A: 44 patients)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Ranitidine 50 mg tid intravenously plus octreotide 100 micrograms tid subcutaneously for three days (Group B: 40 patients)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Ranitidine 50 mg tid intravenously alone (Group A)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Ranitidine 50 mg tid intravenously plus octreotide 100 micrograms tid subcutaneously for three days (Group B)
Number of subjects: 84
Study: 9187166

Group type: EXPERIMENTAL
Intervention: Albuterol (400 microg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ipratropium (80 microg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 1539469

Group type: EXPERIMENTAL
Intervention: Awake fibreoptic intubation under local anaesthesia (Group B)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Endotracheal intubation during general anaesthesia (Group A)
Number of subjects: 70
Study: 3521416

Group type: EXPERIMENTAL
Intervention: Chest ultrasonography (CU)
Number of subjects: 205

Group type: COMPARATOR
Intervention: Decubitus roentgenography
Number of subjects: 205
Study: 31113646

Group type: EXPERIMENTAL
Intervention: Low fructose diet for 2 weeks
Number of subjects: 88

Group type: COMPARATOR
Intervention: Positive 25 g fructose breath test
Number of subjects: 88
Study: 28870461

Group type: EXPERIMENTAL
Intervention: Omalizumab treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PBMC FcεRIα mRNA expression measured on study entry
Number of subjects: 0
Study: 27560098

Group type: EXPERIMENTAL
Intervention: Hair transplant
Number of subjects: 122
Study: 24612976

Group type: EXPERIMENTAL
Intervention: Successful antimicrobial treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 22691757

Group type: EXPERIMENTAL
Intervention: Concurrent cisplatin chemoradiotherapy supplemented with concurrent gemcitabine and adjuvant gemcitabine/cisplatin
Number of subjects: 515

Group type: COMPARATOR
Intervention: Concurrent cisplatin chemoradiotherapy
Number of subjects: 515
Study: 19438846

Group type: EXPERIMENTAL
Intervention: 800 mg mesalazine three times daily for 8 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 17519064

Group type: EXPERIMENTAL
Intervention: C.E.R.A. (continuous erythropoietin receptor activator) administered subcutaneously at doses determined by previous epoetin therapy (0.4/150, 0.8/150, 1.2/150)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: C.E.R.A. (continuous erythropoietin receptor activator) administered subcutaneously once monthly (Q4W)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: C.E.R.A. (continuous erythropoietin receptor activator) administered subcutaneously
Number of subjects: 137

Group type: COMPARATOR
Intervention: Epoetin therapy administered 1-3 times/week (previous treatment before switching to C.E.R.A.)
Number of subjects: 137
Study: 15352962

Group type: EXPERIMENTAL
Intervention: Remifentanil 0.5 micro g kg(‐1) min(‐1)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 11192307

Group type: EXPERIMENTAL
Intervention: Leukocyte filtration during reperfusion (group I; n = 19)
Number of subjects: 38

Group type: COMPARATOR
Intervention: No leukocyte filtration during reperfusion (group II; n = 19)
Number of subjects: 38
Study: 9709770

Group type: EXPERIMENTAL
Intervention: Topical instillation of 2% dorzolamide hydrochloride
Number of subjects: 25

Group type: COMPARATOR
Intervention: Topical placebo
Number of subjects: 25
Study: 7557064

Group type: EXPERIMENTAL
Intervention: Levocabastine ophthalmic solution (0.5 mgrs/ml), one drop every 12 hours for seven days
Number of subjects: 40

Group type: COMPARATOR
Intervention: Saline solution drops, one drop every 12 hours for seven days
Number of subjects: 40
Study: 2492377

Group type: EXPERIMENTAL
Intervention: Staff model HMO
Number of subjects: 693

Group type: COMPARATOR
Intervention: Fee-for-service plans (with cost-sharing)
Number of subjects: 693

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 693
Study: 1228092

Group type: EXPERIMENTAL
Intervention: Brondiletten retard
Number of subjects: 53
Study: 30852136

Group type: EXPERIMENTAL
Intervention: Reduced-dose combination chemotherapy with S-1 (20 mg/m2 orally twice daily on days 1–14) and oxaliplatin (100 mg/m2 intravenously on day 1 every 3 weeks)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Full-dose monotherapy with S-1 (30 mg/m2 orally twice daily on days 1–14 every 3 weeks)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Full-dose monotherapy with S-1
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Reduced-dose combination chemotherapy with S-1 and oxaliplatin
Number of subjects: 160
Study: 27338125

Group type: EXPERIMENTAL
Intervention: 8-month exercise intervention (regular contact with an exercise physiologist over the phone or home delivered face to face)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: 8-month exercise intervention
Number of subjects: 134
Study: 25363733

Group type: EXPERIMENTAL
Intervention: Intravenous paricalcitol injection
Number of subjects: 255

Group type: COMPARATOR
Intervention: Intravenous maxacalcitol injection
Number of subjects: 255
Study: 24466598

Group type: EXPERIMENTAL
Intervention: SMS intervention group receiving diabetes-related information and lifestyle modification
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group with usual care
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: SMS intervention group
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 54
Study: 21996644

Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 11
Study: 19816383

Group type: EXPERIMENTAL
Intervention: Dynamic care pathway for advanced therapy in diabetic foot ulceration
Number of subjects: 0
Study: 22764248

Group type: EXPERIMENTAL
Intervention: Tolcapone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16312178

Group type: EXPERIMENTAL
Intervention: QD arm (tenofovir, didanosine, efavirenz)
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: QD arm (high didanosine doses)
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: QD arm
Number of subjects: 390

Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: QD arm (individuals with HIV-1 RNA <400 copies/ml)
Number of subjects: 390

Group type: COMPARATOR
Intervention: Control arm (individuals with HIV-1 RNA <400 copies/ml)
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: QD arm (high vs low didanosine doses)
Number of subjects: 390
Study: 12359169

Group type: EXPERIMENTAL
Intervention: Statistical k nearest‐neighbor methods
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Statistical projection pursuit method
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Extended projection pursuit method
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Combinations of selected ERP time segments across different electrodes
Number of subjects: 32
Study: 10214656

Group type: EXPERIMENTAL
Intervention: Music condition
Number of subjects: 15

Group type: COMPARATOR
Intervention: Nonmusic condition
Number of subjects: 15
Study: 7818154

Group type: EXPERIMENTAL
Intervention: Recombinant tissue plasminogen activator (rt‐PA)
Number of subjects: 312
Study: 2361594

Group type: EXPERIMENTAL
Intervention: Blue-green argon laser
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Red krypton laser
Number of subjects: 16

Group type: COMPARATOR
Intervention: Both lasers
Number of subjects: 16
Study: 469699

Group type: EXPERIMENTAL
Intervention: Expectancy of control over electric shock (three conditions)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Repeated measures of state anxiety
Number of subjects: 72
Study: 29809075

Group type: EXPERIMENTAL
Intervention: SHP465 mixed amphetamine salts (MAS) 50 or 75 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Immediate-release MAS (MAS IR) 25 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SHP465 mixed amphetamine salts (MAS)
Number of subjects: 0
Study: 27168455

Group type: EXPERIMENTAL
Intervention: Fermented milk product (100 g, twice daily for 3 months)
Number of subjects: 599

Group type: COMPARATOR
Intervention: Control product (100 g, twice daily for 3 months)
Number of subjects: 599
Study: 25913823

Group type: EXPERIMENTAL
Intervention: Energetic program (self-management group program)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 0
Study: 23070058

Group type: EXPERIMENTAL
Intervention: PAF-R antagonist CV3988
Number of subjects: 48

Group type: COMPARATOR
Intervention: Poor glycaemic control
Number of subjects: 48

Group type: COMPARATOR
Intervention: Good glycaemic control
Number of subjects: 48
Study: 20884953

Group type: EXPERIMENTAL
Intervention: Therapist-delivered online cognitive-behavioural therapy (CBT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 18579828

Group type: EXPERIMENTAL
Intervention: Quick Clinical (QC) with meta-search filters
Number of subjects: 75

Group type: COMPARATOR
Intervention: Library Model (LM) without meta-search filters
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Quick Clinical (QC)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Library Model (LM)
Number of subjects: 75
Study: 16856976

Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 37
Study: 14700438

Group type: EXPERIMENTAL
Intervention: Professional cleaning with bait traps containing insecticide
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Professional cleaning with bait traps without insecticide
Number of subjects: 49

Group type: COMPARATOR
Intervention: No cleaning or bait traps
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Professional cleaning (both with and without insecticide)
Number of subjects: 49
Study: 10992833

Group type: EXPERIMENTAL
Intervention: rapacuronium 1.5 mg kg‐1
Number of subjects: 60

Group type: COMPARATOR
Intervention: rocuronium 0.6 mg kg‐1
Number of subjects: 60
Study: 8877664

Group type: EXPERIMENTAL
Intervention: Coronally advanced flap combined with a free connective tissue graft
Number of subjects: 67

Group type: COMPARATOR
Intervention: Coronally advanced flap alone
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Both test and control groups
Number of subjects: 67
Study: 1842141

Group type: COMPARATOR
Intervention: Nifedipine (60 mg/day for 3 weeks)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Diltiazem (270 mg/day for 3 weeks)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 6137293

Group type: EXPERIMENTAL
Intervention: Surgical therapy (coronary artery bypass surgery)
Number of subjects: 780

Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 780
Study: 29926158

Group type: COMPARATOR
Intervention: Hydroxyurea (HU) and placebo, 18 patients
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Resveratrol/piperine and placebo, 16 patients
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Hydroxyurea (HU) and resveratrol/piperine, 20 patients
Number of subjects: 54
Study: 27410162

Group type: EXPERIMENTAL
Intervention: Progressive resistance exercise program (10 weeks)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Health status monitoring (Control group)
Number of subjects: 28
Study: 24839887

Group type: EXPERIMENTAL
Intervention: Psychoeducational problem-solving group intervention (n = 27)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Nonstructured group intervention (n = 28)
Number of subjects: 55
Study: 23063316

Group type: EXPERIMENTAL
Intervention: Ciclosporin (2 mg/kg per day for 1 week, followed by oral drug until day 98)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Infliximab (5 mg/kg on days 0, 14, and 42)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Ciclosporin
Number of subjects: 115

Group type: COMPARATOR
Intervention: Infliximab
Number of subjects: 115
Study: 20367484

Group type: EXPERIMENTAL
Intervention: Normobaric hypoxia (HG)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Normoxia (NG)
Number of subjects: 40
Study: 19137912

Group type: EXPERIMENTAL
Intervention: Test product of tinidazole
Number of subjects: 24

Group type: COMPARATOR
Intervention: Reference product of tinidazole
Number of subjects: 24
Study: 15467292

Group type: EXPERIMENTAL
Intervention: Antibiotics (ampicillin and gentamicin for 3 days)
Number of subjects: 148

Group type: COMPARATOR
Intervention: No antibiotics
Number of subjects: 148
Study: 12073051

Group type: EXPERIMENTAL
Intervention: FDG-PET
Number of subjects: 48

Group type: COMPARATOR
Intervention: Bone scan
Number of subjects: 48
Study: 12166532

Group type: EXPERIMENTAL
Intervention: Diet alone (1,200‐1,300 kcal/day)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Exercise alone (five 45 minute sessions per week at 78.4±0.5% maximum heart rate)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Exercise and diet
Number of subjects: 91

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 91
Study: 10223751

Group type: EXPERIMENTAL
Intervention: Laparoscopic-assisted resection
Number of subjects: 201

Group type: COMPARATOR
Intervention: Conventional open surgery
Number of subjects: 201
Study: 7884123

Group type: EXPERIMENTAL
Intervention: In-home primary care by an interdisciplinary team (physician, physical therapist, 24-hour nursing services, geriatric consultation)
Number of subjects: 249

Group type: COMPARATOR
Intervention: Usual care (standard district nurse-administered services at home)
Number of subjects: 249
Study: 2144152

Group type: EXPERIMENTAL
Intervention: Quadrantectomy, axillary dissection and radiotherapy on the ipsilateral breast
Number of subjects: 701

Group type: COMPARATOR
Intervention: Halsted mastectomy
Number of subjects: 701

Group type: EXPERIMENTAL
Intervention: Quadrantectomy
Number of subjects: 701
Study: 512076

Group type: EXPERIMENTAL
Intervention: Anthracene plus UVA light
Number of subjects: 5
Study: 31773208

Group type: EXPERIMENTAL
Intervention: E2 valerate (2, 4, 6, or 12 mg)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study: 30760332

Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy (NPWT) with silver-impregnated dressings via RENASYS TOUCH™ vacuum pump
Number of subjects: 104

Group type: COMPARATOR
Intervention: Standard therapy consisting of Acticoat™ and Mepitel™
Number of subjects: 104
Study: 28668276

Group type: EXPERIMENTAL
Intervention: Walking group intervention (11-week, weekly 1-hour sessions, maintenance of 10,000 steps/day)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Walking group intervention
Number of subjects: 41

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 41
Study: 25803441

Group type: EXPERIMENTAL
Intervention: CPIA (continuous propofol infusion by anesthesiologist)
Number of subjects: 154

Group type: COMPARATOR
Intervention: IMIE (intermittent midazolam/propofol injection by endoscopist)
Number of subjects: 154
Study: 23969308

Group type: EXPERIMENTAL
Intervention: Decitabine therapy with dose delays or dose reductions (DD/DR) after achieving best objective response.
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Decitabine therapy with dose delays or dose reductions (DD/DR) before achieving best objective response.
Number of subjects: 122

Group type: COMPARATOR
Intervention: No dose delays or dose reductions (no DD/DR).
Number of subjects: 122
Study: 21362272

Group type: EXPERIMENTAL
Intervention: Intrathecal 0.5% hyperbaric ropivacaine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intrathecal bupivacaine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Ropivacaine compared to bupivacaine
Number of subjects: 40
Study: 19089438

Group type: EXPERIMENTAL
Intervention: Betamethasone treatment (intramuscular injection of 12 mg every 24 hours)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Betamethasone treatment
Number of subjects: 60
Study: 17898365

Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch 130/0.4
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Modified gelatin solution
Number of subjects: 66

Group type: COMPARATOR
Intervention: Ringer lactate solution
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Colloids (hydroxyethyl starch and modified gelatin)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Fibrinogen concentrate (Hemocomplettan) administered at 30 mg/kg
Number of subjects: 66
Study: 15476757

Group type: EXPERIMENTAL
Intervention: Woolen hats
Number of subjects: 126

Group type: COMPARATOR
Intervention: Cotton diapers
Number of subjects: 126
Study: 11508513

Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray (MFNS)
Number of subjects: 329

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 329

Group type: COMPARATOR
Intervention: Mometasone furoate nasal spray (MFNS) and Placebo
Number of subjects: 329
Study: 10166597

Group type: EXPERIMENTAL
Intervention: Outreach visits by trained nurse facilitators
Number of subjects: 95

Group type: COMPARATOR
Intervention: Feedback method (provision of a feedback report with advice)
Number of subjects: 95
Study: 7911010

Group type: EXPERIMENTAL
Intervention: Azelastine nasal spray (0.14 mg/nostril twice daily)
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Terfenadine (60 mg twice daily)
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Azelastine nasal spray
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Terfenadine
Number of subjects: 219
Study: 2906953

Group type: EXPERIMENTAL
Intervention: Propranolol (acute and chronic treatment)
Number of subjects: 51

Group type: COMPARATOR
Intervention: i.v. Metoprolol (acute treatment)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Atenolol, Metoprolol, Pindolol, Propranolol (chronic treatment)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Beta-blockade (acute and chronic)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Beta-blockade (5-month treatment)
Number of subjects: 51
Study: 29893790

Group type: EXPERIMENTAL
Intervention: Palbociclib in combination with endocrine therapy (ET)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Palbociclib monotherapy
Number of subjects: 115